The lack of efficacy of idelalisib in MM, as well as in acute myeloid leukemia and myeloproliferative neoplasms, is attributed to a highly variable p110-δ active site and a high degree of conformational flexibility that leads to poor inhibitor binding. The gene discussed is PIK3CD; the disease is acute myeloid leukemia.